CDCharlotte Debiais-Deschamps

Charlotte Debiais-Deschamps

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charlotte Debiais-Deschamps has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • A. Loupy

    Paris Transplant Research Center For Organ Transplantation, Inserm, Unité Mixte De Recherche-S970, Service De Transplantation Rénale, Hôpital Necker, Assistance Publique Hôpitaux De Paris, Paris, France

    1 shared publication
  • Adam Mussell

    Renal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

    1 shared publication
  • Agathe Truchot

    Paris Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France

    1 shared publication
  • Aiko P. J. de Vries

    Leiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden, the Netherlands

    1 shared publication
  • Alexandre Loupy

    Paris Institute for Transplantation and Organ Regeneration, Institut National de la Santé et de la Recherche Médicale U970, Université Paris Cité, Paris, France

    1 shared publication
  • Anne Scemla

    Department of Kidney Transplantation, Necker Hospital, Assistance Publique—Hôpitaux de Paris, Université Paris Cité, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    A Prediction Model for Risk of Death in Kidney Transplant Recipients

    by Charlotte Debiais-Deschamps, Marc Raynaud, Agathe Truchot, Yannis Lombardi, Gillian Divard, Vivek A. Rudrapatna, Soufian Meziyerh, Jesper Kers, Danny van der Helm, Aiko P. J. de Vries, et al.

    Importance: Accurate prediction of patient mortality after kidney transplant is an unmet need. Objective: To develop and validate an integrative prediction model that predicts short- and long-term patient mortality for kidney recipients. Design, Setting, and Participants: This international cohort study included patients who underwent transplants between 2004 and 2023 from 14 academic medical centers from Europe and the US. The derivation cohort consisted of 1566 consecutive adult kidney recipients in a deeply phenotyped cohort prospectively recruited in 1 French center between 2004 and 2014. External validation cohorts consisted of 10 951 kidney recipients from 7 centers in France, 3 centers in Europe, and 3 centers in North America who underwent kidney transplants between 2006 and 2023. Data were analyzed from January 2023 to June 2025. Main Outcome and Measures: All-cause mortality was assessed, and 121 candidate prognostic factors, comprising demographics and clinical, biological, imaging, and immunological parameters, were collected. Results: Among 12 517 kidney transplant recipients, including 1566 in the derivation cohort (mean [SD] age, 50.05 [14.31] years; 942 male [60.15%]) and 10 951 in validation cohorts (mean [SD] age, 53.32 [13.97] years; 6766 male [61.78%]), 2486 patients (19.9%) died after a median (IQR) follow-up of 5.08 (2.97-7.00) years. Fourteen prognostic factors (including clinical, biological, and imaging risk factors) were independently associated with patient death (eg, patient age: hazard ratio per 1-year increase in age, 1.07 [95% CI, 1.06-1.08]; P < .001) and were combined into a risk prediction model (mBox). The model exhibited accurate calibration and discrimination in the derivation cohort, with C statistics of 0.82 (95% CI, 0.77-0.87) and 0.80 (95% CI, 0.78-0.82) at 1 and 10 years, respectively, after the transplant. Abbreviated models were developed and validated to ensure model generalizability. Performance of abbreviated models was confirmed in external validation cohorts from France (C statistic, 0.76 [95% CI, 0.73-0.78]), Europe (C statistic, 0.74 [95% CI, 0.72-0.76]), the US (C statistic, 0.74 [95% CI, 0.70-0.78]), the Greater Paris University Hospital database (C statistic, 0.79 [95% CI, 0.77-0.81]), and the University of California at San Francisco database (C statistic, 0.70 [95% CI, 0.65-0.74]). The model was also validated in a series of subpopulations (eg, women vs men: C statistic, 0.81 [95% CI, 0.77-0.84] vs 0.79 [95% CI, 0.77-0.82]) and clinical scenarios (eg, before COVID-19 era: C statistic, 0.79 [95% CI, 0.77-0.81]) with good and stable performance. Conclusions and Relevance: In this study, an accurate prediction model for mortality among kidney recipients, computable at the time of transplant, was developed and externally validated. Results suggest that this model may help stratify patient risk of death, allowing for improved medical decisions.

  • Open Access

    Long-term Graft and Patient Survival in Kidney Transplant Recipients With High Levels of Preformed DSAs (MFI > 3000): A Propensity Score–matched Analysis

    by Charlotte Debiais-Deschamps, Lucile Amrouche, Marion Rabant, Jean-Paul Duong Van Huyen, Carole Burger, Camille Roger, Marie-Benedicte Le Stang, Antoine Troger, Juliette Leon, Frank Martinez, et al.

    Background.: Kidney transplant recipients with preformed donor-specific antibodies (DSAs) are at higher risk for antibody-mediated rejection (AMR) and graft failure. This study assesses outcomes during a 15-y period, comparing patients with high levels of preformed DSAs to a matched cohort of recipients without DSA. Methods.: This retrospective study includes 95 patients with high levels of preformed DSAs, defined by DSA levels (mean fluorescence intensity > 3000). Using propensity score matching, 88 of these patients were matched to 154 recipients without DSA based on age, sex, transplant year, cold ischemia time, and other clinical factors. Outcomes included occurrence of AMR, T cell–mediated rejection, and long-term allograft and patient survival. Results.: The mean follow-up after transplantation was 11.9 ± 5.6 y. Among the matched patients, kidney allograft survival rates after transplantation at 5, 10, and 15 y were 90.5%, 79.5%, and 72.8% for the patients without preformed DSA and 86.7%, 60.2%, and 47.6% for the patients with high levels of preformed DSAs ( P = 0.002). The patient survival rates after transplantation at 5, 10, and 15 y were 91.3%, 72.3%, and 57.9% for the patients without preformed DSA and 86.4%, 71.2%, and 49.0% for the patients with high levels of preformed DSAs ( P = 0.206). More AMR occurred in the patients with high levels of preformed DSAs ( P < 0.001) without significant difference in T cell–mediated rejection ( P = 0.203). Conclusions.: Although patients with high levels of preformed DSAs have a higher risk of graft loss, their long-term survival did not differ significantly from recipients without DSA, supporting the use of intensive immunosuppression in this population.


  • Modélisation des déterminants de la mortalité des patients transplantés rénaux et réalisation d’un score prédictif à 1 an post-transplantation. Étude monocentrique de survie

    by C. Debiais-Deschamps, O. Aubert, M. Racapé, G. Divard, X. Jouven, C. Legendre, A. Loupy

    Introduction: L’objectif de l’étude est de développer un modèle statistique intégrant les facteurs de risque les plus pertinents, disponibles avant ou durant la première année de la transplantation, afin de prédire la mortalité des patients transplantés rénaux. Description: 160 variables, issues du donneur, du receveur et de la greffe, ainsi que des données biologiques et d’imagerie, ont été collectées au jour de la transplantation et durant la première année suivant la greffe pour les patients consécutivement transplantés entre 2004 et 2014 au sein d’un centre français. Méthodes: Un modèle de Cox univarié puis multivarié est réalisé afin de développer un score de prédiction individuel de mortalité, ensuite amélioré par une technique de régression supervisée de Lasso afin de sélectionner les facteurs de risque les plus prédictifs de la mortalité des patients, jusqu’à 10 ans après la greffe. Résultats: 1446 patients ont été inclus dans l’étude. Parmi toutes les variables disponibles pour chaque patient, 19 ont été retenues par la méthode de Lasso. Les variables les plus prédictives du décès post-transplantation sont composées de données concernant le receveur, parmi lesquelles l’âge, l’antécédent de cancer, le diabète, la Broncho-Pneumopathie Chronique Obstructive, les évènements cardio-vasculaires, les troubles du rythme supraventriculaire, les antécédents psychiatriques ou l’antécédent d’hépatite C ; de données de la greffe comme la reprise retardée de fonction rénale ; des complications cardiovasculaires ou néoplasiques survenues au cours de la première année de la greffe, ainsi que de 7 variables biologiques. Le score obtenu possède une calibration optimale et une bonne discrimination à 10 ans (C-statistique = 0,81, IC : 0,78-0,83). Conclusion: Notre modèle démontre une performance prédictive élevée, supérieure à celle des autres scores actuellement disponibles. Cet outil d’aide à la décision permet d’améliorer la stratification du risque et autorise un suivi plus personnalisé des patients transplantés rénaux.

  • Open Access

    Where to Biopsy to Detect Helicobacter pylori and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach

    by Maxime Pichon, Cong Tri Tran, Gaëtan Motillon, Charlotte Debiais, Sylvain Gautier, Marie Aballea, Julie Cremniter, Philippe Vasseur, David Tougeron, Magali Garcia, et al.

    This study aims to determine the gastric distribution, density, and diversity of Helicobacter pylori infection. Subtotal resection of the stomachs of three H. pylori-infected and asymptomatic obese patients were collected after a sleeve gastrectomy. Distribution and density of H. pylori were determined using culture and RT-PCR on multiple gastric sites (88, 176, and 101 biopsies per patient). Diversity of H. pylori strains was studied using antibiotic susceptibility testing, random amplified polymorphism DNA (RAPD) typing and cagA gene detection on single-colony isolates (44, 96, and 49 isolates per patient). H. pylori was detected in nearly all analyzed sites (354/365 biopsies, 97%). Antral density was higher in one patient only. The three stomachs were almost exclusively infected by an antibiotic-susceptible strain. One clarithromycin-resistant isolate in one biopsy was detected in two stomachs (1/44 and 1/49 isolates), while in the third one, eight (8/96 isolates) metronidazole-resistant isolates were detected. DNA typing showed infection with cagA-negative strains for one patient, cagA-positive strains for a second patient and the third patient was infected with two different strains of distinct cagA genotypes. Infection with H. pylori is shown to spread to the whole surface of the stomach, but a possibility of minor sub-population of antibiotic-resistant clones, undetectable in routine practice.